Speaker
Wei Chen
(Peking University Health Science Center, Beijing)
Description
Background: TNBC accounts for 15-20% of breast cancers with aggressive behavior and poor prognosis.
Objective: To identify epigenetic modifications in ctDNA as non-invasive prognostic biomarkers.
Methods: Genome-wide methylation profiling of ctDNA from 245 TNBC patients using bisulfite sequencing, 36-month follow-up.
Results: 12 DMRs predicted PFS (HR=3.42, p<0.001). Methylation signature outperformed clinicopathological features (C-index: 0.78 vs 0.63).
Conclusion: ctDNA epigenetic profiling provides a non-invasive prognostic tool for TNBC.
Author
Wei Chen
(Peking University Health Science Center, Beijing)